



## Ensuring Patient Safety

# Network of global Professionals

Our Global Drug Safety Department is responsible for monitoring, analysing and reporting on the safety of our medicines at all stages of the product lifecycle – from volunteers and patients participating in clinical trials of a new compound to patients taking a medicine once it is available by prescription.

The Drug Safety Department is managed by a global team of drug safety professionals including doctors, pharmacists, nurses and other scientists. They are supported by local safety specialists in each country where we operate. In total, close to 500 Roche personnel are associated with the Drug Safety Department, which is managed through a strong governance framework.

Roche has established a systematic process for reporting, collecting and analysing safety information to optimise patient safety throughout the entire life of the medicine, in full compliance with local and global regulations and guidance.

Specialists assigned to each medical product continually review all reported adverse events for their product to identify any potential change in its safety profile. This could be, for example, a new adverse event that we have not previously seen, or an increase in the frequency or severity of a known adverse event.

As some information on side effects and related risks may be known only after a drug is used in large numbers of patients in the wider population, Roche has implemented a safety risk management process. This process begins in the early stages of the medicine's development. It assists us in identifying potential side effects before they occur, enabling appropriate preventative strategies to be devised and implemented. Our dedicated Safety Risk Management Group is responsible for ensuring this process is consistent throughout the entire lifecycle of each medicine.